Skip to Main Content

Revolution Medicines on Saturday presented updated data to bolster the case for its lead cancer drug — designed to stop tumor growth by throttling back mutations in a common cell-signaling pathway.

The drug, called RMC-4630, won’t shrink tumors very much on its own. The drug’s main purpose will be as a backbone of combination treatments. The first test of this pairing strategy will come toward the end of the year, when Amgen reads out results of a study using RMC-4630 to boost the efficacy of sotorasib, its mutant KRAS-blocking lung cancer drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!